A 48 week, open label, Non-Comparative, Multicentre, Phase IIIb Study to Evaluate the Efficacy and safety of the Lipid-Regulating agent Rosuvastatin in the treatment of subjects with Fredrickson Type IIa and Type IIb Dyslipidaemia, including Heterozygous Familial Hypercholesterolaemia.
18 Years - 150 Years
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
No locations available